The concept of a closed-loop therapeutic system is not new. People with type 1 diabetes have lived with versions of it for decades: continuous glucose monitors feed real-time data into an insulin pump, and a control algorithm decides how much hormone to deliver without any manual input. These artificial pancreas systems, first envisioned as servomechanisms in the early 1960s and now cleared by regulators worldwide, demonstrate that autonomous drug delivery is technically and clinically feasible. CLOOR systems aim to apply the same three-component architecture — sensing, actuation and control — to a very different and far more time-critical emergency. Instead of stabilizing a metabolic value over hours, the device must detect a lethal respiratory crisis and counteract it within a narrow window measured in minutes.

The sensing problem is the first and arguably hardest piece. Opioids kill by suppressing respiration, so the most direct overdose signature is a slowing or stopping of breathing. Fentanyl and its synthetic cousins act rapidly on mu-opioid receptors in the brainstem, including the Kölliker–Fuse and parabrachial complexes, sometimes driving breathing to a halt before a person even loses consciousness. Candidate detection modalities therefore include respiratory rate, blood oxygen saturation, chest wall movement, heart rate and cerebral oxygenation. Smartphone-based systems have already demonstrated that acoustic signals and radar-like sonar can capture the apnea characteristic of overdose, and consumer smartwatches have recently received regulatory attention for automated loss-of-pulse detection. Yet each sensing route carries technical liabilities: wearable optical sensors degrade with poor skin contact, pulse oximetry accuracy varies with skin pigmentation, and motion artifacts plague real-world wear. No single validated biomarker currently defines the moment an overdose becomes lethal, which is a stark contrast to the well-characterized glucose thresholds that anchor insulin closed-loop systems.

Once an overdose is detected, the device must act. Prototypes have explored a remarkable range of actuation strategies. Wearable injectors can fire a preloaded dose of naloxone intramuscularly on command, while implantable devices have been designed to sit quietly beneath the skin and respond autonomously to hypoxia. One autonomous implant described in Science Advances integrates sensing and drug delivery in a single unit intended to prevent death from overdose in high-risk individuals. Other designs favor minimally invasive microneedle arrays or patches that combine accelerometer-based respiration tracking with a stored antidote reservoir. The pharmacology matters as much as the hardware: naloxone’s short half-life means that fentanyl can outlast the antidote and reassert its respiratory suppression, a phenomenon that has pushed clinicians toward higher and repeated doses in the synthetic opioid era. Longer-acting antagonists such as nalmefene offer an alternative, though their adoption in community settings remains debated because prolonged reversal can also trigger withdrawal and complicate patient behavior.

Between sensor and actuator sits the control algorithm, the component the researchers identify as the least mature. The algorithm must fuse noisy physiological streams, distinguish a true overdose from sleep, exercise, sedation or sensor failure, and decide when the benefit of automatic naloxone delivery outweighs the risk of a false alarm. Machine learning approaches, including deep-learning respiratory rate detection and personalized Gaussian-process models of individual baselines, offer a path to robust decision-making under uncertainty. Federated learning could allow algorithms to improve across large user populations without centralizing sensitive health data. Still, the authors emphasize that unlike sepsis management or diabetes control, there is no consensus intervention threshold for overdose, no clinically validated definition of the physiological point of no return, and limited clinical evidence from which to train and validate decision systems. Whole-body physiology models that simulate fentanyl-induced respiratory depression and naloxone reversal are helping fill that gap computationally, but translational models cannot fully substitute for human evidence.

The regulatory landscape for CLOOR devices is as complicated as their engineering. Autonomous emergency intervention raises questions that existing frameworks were not designed to answer. The United States Food and Drug Administration has issued guidance on physiological closed-loop control technology and has convened joint public workshops with NIDA to define what evidence would justify approving a device that acts without a patient’s conscious participation. Precedents from automated insulin delivery, including the first regulatory clearance of an open-source automated insulin dosing algorithm, suggest a route is possible, but overdose reversal devices face a different evidentiary burden: their target event is rare, unpredictable and ethically impossible to reproduce in a controlled trial. De novo classifications and 510(k) clearances for related sensors and pulse-detection features hint at how regulators may decompose the problem, yet none of these pathways has yet produced an approved autonomous overdose-reversing device.

Even a technically flawless, regulator-approved device would fail if the people who need it do not wear it. Stigma, distrust and the realities of daily life shape adoption as powerfully as any engineering specification. Studies of people who use opioids in Philadelphia and elsewhere reveal meaningful willingness to use devices capable of detecting and reversing overdose, but also persistent concerns about privacy, involuntary data sharing, battery life, comfort and whether the device might summon police instead of medical help. Community-engaged design efforts, in which people with lived experience co-develop wearable biosensors, have emerged as a model for building the trust that purely technology-driven projects lack. The authors also point to a quieter problem shared by all wearables: attrition. Users abandon tracking devices at high rates, and a device worn only intermittently protects no one during an overdose.

Equity and distribution complete the translational puzzle. The populations at highest risk of fatal overdose — people who inject drugs, people experiencing homelessness, people in rural areas far from emergency services — are precisely those least likely to access expensive novel medical technology. A CLOOR system that costs more than the communities can absorb or that requires maintenance infrastructure unavailable outside clinical settings would widen the survival gap it was built to close. The researchers argue for affordability and distribution strategies engineered from the outset, drawing on lessons from mobile medical systems designed for equitable health care, and for modular architectures that could lower manufacturing costs and speed iterative improvement.

What emerges from the analysis is neither a dismissal of CLOOR technology nor a promise of imminent arrival, but a roadmap. The authors synthesize engineering, clinical, regulatory and public health perspectives into a sequence of priorities: validate overdose biomarkers through controlled human and computational studies; build and benchmark multi-sensor data fusion and control algorithms against realistic physiological variability; establish regulatory pathways that can evaluate autonomous emergency intervention responsibly; design devices around user needs identified through genuine community partnership; and construct distribution models that deliver the technology to those with the most to lose. The fentanyl era has compressed the time available for human rescue to almost nothing. Whether machines can be trusted to take those minutes back, reliably and equitably, is now one of the most consequential questions in bioengineering — and the answer, the researchers conclude, will depend as much on regulation, trust and access as on sensors and algorithms.

Subject of Research: Closed-loop opioid overdose reversal systems that autonomously detect respiratory depression and deliver naloxone without bystander intervention.

Article Title: Opioid overdose detection and reversal with closed-loop systems

Article References: Angelone, L. M., & Koustova, E. (2026). Opioid overdose detection and reversal with closed-loop systems. Nature Reviews Bioengineering. https://doi.org/10.1038/s44222-026-00492-w

Image Credits: AI Generated

DOI: 10.1038/s44222-026-00492-w

Keywords: opioid overdose, naloxone, closed-loop systems, wearable sensors, respiratory depression, drug delivery, FDA regulation, biosensors, fentanyl, public health, translational research, biomedical engineering